nodes	percent_of_prediction	percent_of_DWPC	metapath
Alvimopan—Quinapril—Lisinopril—systemic scleroderma	0.485	0.512	CrCrCtD
Alvimopan—Benazepril—Lisinopril—systemic scleroderma	0.462	0.488	CrCrCtD
Alvimopan—Quinapril—ACE—systemic scleroderma	0.00288	0.535	CrCbGaD
Alvimopan—Benazepril—ACE—systemic scleroderma	0.0025	0.465	CrCbGaD
Alvimopan—Flatulence—Pentoxifylline—systemic scleroderma	0.0013	0.0268	CcSEcCtD
Alvimopan—Back pain—Pentoxifylline—systemic scleroderma	0.00127	0.0263	CcSEcCtD
Alvimopan—Hypokalaemia—Leflunomide—systemic scleroderma	0.00124	0.0257	CcSEcCtD
Alvimopan—Urinary retention—Mycophenolic acid—systemic scleroderma	0.00124	0.0256	CcSEcCtD
Alvimopan—Anaemia—Pentoxifylline—systemic scleroderma	0.00122	0.0251	CcSEcCtD
Alvimopan—Hypokalaemia—Mycophenolic acid—systemic scleroderma	0.00119	0.0245	CcSEcCtD
Alvimopan—Back pain—Mometasone—systemic scleroderma	0.0011	0.0227	CcSEcCtD
Alvimopan—Urinary retention—Mycophenolate mofetil—systemic scleroderma	0.000977	0.0202	CcSEcCtD
Alvimopan—Dyspepsia—Pentoxifylline—systemic scleroderma	0.000946	0.0195	CcSEcCtD
Alvimopan—Hypokalaemia—Mycophenolate mofetil—systemic scleroderma	0.000935	0.0193	CcSEcCtD
Alvimopan—Urinary tract disorder—Leflunomide—systemic scleroderma	0.000933	0.0193	CcSEcCtD
Alvimopan—Connective tissue disorder—Leflunomide—systemic scleroderma	0.000928	0.0192	CcSEcCtD
Alvimopan—Urethral disorder—Leflunomide—systemic scleroderma	0.000926	0.0191	CcSEcCtD
Alvimopan—Anaemia—Captopril—systemic scleroderma	0.000922	0.019	CcSEcCtD
Alvimopan—Constipation—Pentoxifylline—systemic scleroderma	0.000919	0.019	CcSEcCtD
Alvimopan—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00089	0.0184	CcSEcCtD
Alvimopan—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.000885	0.0183	CcSEcCtD
Alvimopan—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.000883	0.0182	CcSEcCtD
Alvimopan—Malnutrition—Leflunomide—systemic scleroderma	0.000822	0.017	CcSEcCtD
Alvimopan—Dyspepsia—Mometasone—systemic scleroderma	0.000816	0.0168	CcSEcCtD
Alvimopan—Flatulence—Leflunomide—systemic scleroderma	0.00081	0.0167	CcSEcCtD
Alvimopan—Anaemia—Azathioprine—systemic scleroderma	0.000805	0.0166	CcSEcCtD
Alvimopan—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000801	0.0165	CcSEcCtD
Alvimopan—Urethral disorder—Lisinopril—systemic scleroderma	0.000795	0.0164	CcSEcCtD
Alvimopan—Back pain—Leflunomide—systemic scleroderma	0.000795	0.0164	CcSEcCtD
Alvimopan—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000784	0.0162	CcSEcCtD
Alvimopan—Flatulence—Mycophenolic acid—systemic scleroderma	0.000773	0.016	CcSEcCtD
Alvimopan—Anaemia—Leflunomide—systemic scleroderma	0.00076	0.0157	CcSEcCtD
Alvimopan—Back pain—Mycophenolic acid—systemic scleroderma	0.000759	0.0157	CcSEcCtD
Alvimopan—Anaemia—Mycophenolic acid—systemic scleroderma	0.000725	0.015	CcSEcCtD
Alvimopan—Dyspepsia—Captopril—systemic scleroderma	0.000717	0.0148	CcSEcCtD
Alvimopan—Malnutrition—Lisinopril—systemic scleroderma	0.000706	0.0146	CcSEcCtD
Alvimopan—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000702	0.0145	CcSEcCtD
Alvimopan—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000699	0.0144	CcSEcCtD
Alvimopan—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000697	0.0144	CcSEcCtD
Alvimopan—Constipation—Captopril—systemic scleroderma	0.000696	0.0144	CcSEcCtD
Alvimopan—Flatulence—Lisinopril—systemic scleroderma	0.000696	0.0144	CcSEcCtD
Alvimopan—Back pain—Lisinopril—systemic scleroderma	0.000683	0.0141	CcSEcCtD
Alvimopan—Anaemia—Lisinopril—systemic scleroderma	0.000653	0.0135	CcSEcCtD
Alvimopan—Hypokalaemia—Prednisone—systemic scleroderma	0.000634	0.0131	CcSEcCtD
Alvimopan—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000619	0.0128	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000613	0.0127	CcSEcCtD
Alvimopan—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00061	0.0126	CcSEcCtD
Alvimopan—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000599	0.0124	CcSEcCtD
Alvimopan—Dyspepsia—Leflunomide—systemic scleroderma	0.000591	0.0122	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000579	0.012	CcSEcCtD
Alvimopan—Constipation—Leflunomide—systemic scleroderma	0.000574	0.0118	CcSEcCtD
Alvimopan—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000572	0.0118	CcSEcCtD
Alvimopan—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000563	0.0116	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000553	0.0114	CcSEcCtD
Alvimopan—Constipation—Mycophenolic acid—systemic scleroderma	0.000547	0.0113	CcSEcCtD
Alvimopan—Dyspepsia—Lisinopril—systemic scleroderma	0.000508	0.0105	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000498	0.0103	CcSEcCtD
Alvimopan—Constipation—Lisinopril—systemic scleroderma	0.000493	0.0102	CcSEcCtD
Alvimopan—Connective tissue disorder—Prednisone—systemic scleroderma	0.000474	0.00978	CcSEcCtD
Alvimopan—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000445	0.00918	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000436	0.009	CcSEcCtD
Alvimopan—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000432	0.00892	CcSEcCtD
Alvimopan—Malnutrition—Prednisone—systemic scleroderma	0.00042	0.00866	CcSEcCtD
Alvimopan—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000398	0.00821	CcSEcCtD
Alvimopan—Urethral disorder—Methotrexate—systemic scleroderma	0.000395	0.00815	CcSEcCtD
Alvimopan—Anaemia—Prednisone—systemic scleroderma	0.000388	0.00801	CcSEcCtD
Alvimopan—Malnutrition—Methotrexate—systemic scleroderma	0.000351	0.00724	CcSEcCtD
Alvimopan—Back pain—Methotrexate—systemic scleroderma	0.000339	0.007	CcSEcCtD
Alvimopan—Anaemia—Methotrexate—systemic scleroderma	0.000324	0.00669	CcSEcCtD
Alvimopan—Dyspepsia—Prednisone—systemic scleroderma	0.000301	0.00622	CcSEcCtD
Alvimopan—Constipation—Prednisone—systemic scleroderma	0.000293	0.00605	CcSEcCtD
Alvimopan—Dyspepsia—Methotrexate—systemic scleroderma	0.000252	0.0052	CcSEcCtD
Alvimopan—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000247	0.0051	CcSEcCtD
